Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (20045)	5/5/1998 10:26:00 AM
From: David Bogdanoff	Read Replies (5) \| Respond to of 32384

HN: According to Boston Life Science CEO Hillson on CNBC this morning, the anti-angiogenesis drugs do not specifically target cancer cells. Further, nobody knows if they can entirely eliminate solid tumors or just retard their growth or formation or reduce their size. If they cannot cure a patient by entirely eliminating all tumors, we have a long term usage of the drug scenario. This doesn't look like the perfect treatment some people may think. Clearly, there are side effects with this technology as it currently stands. FWIW, there were numerous comments on companies with anti-angiogenisis drugs mentioned, including Agouron which just announced p. 1-3 clinical trials today, but I did not hear LGND mention. David